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Pharmaceutical manufacturing by three-dimensional printing (3DP) provides unique advantages, 
including individualization potential by associating customizable doses of various active 
pharmaceutical ingredients (APIs) with different release profiles in one drug delivery system (DDS). 
One of the most promising techniques is fused deposition modeling (FDM). The aim of this research 
was to explore FDM-3DP for the development of personalized immediate release (IR) DDSs with 
diclofenac sodium (DS) by applying the quality-by-design (QbD) approach. 
High drug loaded (50%) FDM 3D printable filaments were prepared by hot melt extrusion. Regarding 
the printing process, a systematic assessment of the influence of the selected independent variables 
(design feature, dosage form size and printing resolution) on the quality attributes of the 3D printed 
DDSs was conducted. By adjusting the dimensions of the digital models, tablets with API content in the 
range of 32-75 mg were produced. The optimum formulation represented by a concentric ring design 
tablet with a DS content of 50 mg presented 78% drug release after 5 minutes and 90% drug release 
after 10 minutes. A correlation between the investigated factors and the dissolution performance of 
the dosage forms was found as high-resolution printing (0.1 mm) and greater tablet dimensions 
promoted faster release of the API. 
In conclusion, by employing the QbD approach to investigate the influence of the printing parameters 
and the dimensions of the DDS on the dissolution performance and API content of the dosage forms, 
preparation of tablets with very rapid dissolution and adjustable doses of API was completed. 
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